The TLR4 antagonist Eritoran protects mice from lethal influenza infection
- PMID: 23636320
- PMCID: PMC3725830
- DOI: 10.1038/nature12118
The TLR4 antagonist Eritoran protects mice from lethal influenza infection
Abstract
There is a pressing need to develop alternatives to annual influenza vaccines and antiviral agents licensed for mitigating influenza infection. Previous studies reported that acute lung injury caused by chemical or microbial insults is secondary to the generation of host-derived, oxidized phospholipid that potently stimulates Toll-like receptor 4 (TLR4)-dependent inflammation. Subsequently, we reported that Tlr4(-/-) mice are highly refractory to influenza-induced lethality, and proposed that therapeutic antagonism of TLR4 signalling would protect against influenza-induced acute lung injury. Here we report that therapeutic administration of Eritoran (also known as E5564)-a potent, well-tolerated, synthetic TLR4 antagonist-blocks influenza-induced lethality in mice, as well as lung pathology, clinical symptoms, cytokine and oxidized phospholipid expression, and decreases viral titres. CD14 and TLR2 are also required for Eritoran-mediated protection, and CD14 directly binds Eritoran and inhibits ligand binding to MD2. Thus, Eritoran blockade of TLR signalling represents a novel therapeutic approach for inflammation associated with influenza, and possibly other infections.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3725830/bin/nihms491801f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3725830/bin/nihms491801f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3725830/bin/nihms491801f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3725830/bin/nihms491801f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3725830/bin/nihms491801f5.gif)
Similar articles
-
The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.mBio. 2017 Apr 25;8(2):e00226-17. doi: 10.1128/mBio.00226-17. mBio. 2017. PMID: 28442605 Free PMC article.
-
Novel strategies for targeting innate immune responses to influenza.Mucosal Immunol. 2016 Sep;9(5):1173-82. doi: 10.1038/mi.2015.141. Epub 2016 Jan 27. Mucosal Immunol. 2016. PMID: 26813341 Free PMC article.
-
Targeting myeloid differentiation 2 for treatment of sepsis.Front Biosci (Landmark Ed). 2014 Jun 1;19(6):904-15. doi: 10.2741/4256. Front Biosci (Landmark Ed). 2014. PMID: 24896325 Review.
-
Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.Pharmacol Ther. 2012 Mar;133(3):291-8. doi: 10.1016/j.pharmthera.2011.11.001. Epub 2011 Nov 19. Pharmacol Ther. 2012. PMID: 22119168 Review.
-
Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.Circulation. 2006 Jul 4;114(1 Suppl):I270-4. doi: 10.1161/CIRCULATIONAHA.105.000901. Circulation. 2006. PMID: 16820585
Cited by
-
Damage sensing through TLR9 Promotes Viral Clearance and Recovery During Influenza Infection.bioRxiv [Preprint]. 2024 Mar 6:2024.03.04.583378. doi: 10.1101/2024.03.04.583378. bioRxiv. 2024. PMID: 38496452 Free PMC article. Preprint.
-
Salmonella Typhimurium infection inhibits macrophage IFNβ signaling in a TLR4-dependent manner.bioRxiv [Preprint]. 2024 Mar 5:2024.03.05.583530. doi: 10.1101/2024.03.05.583530. bioRxiv. 2024. PMID: 38496427 Free PMC article. Preprint.
-
SARS-CoV-2 Omicron Spike shows strong binding affinity and favourable interaction landscape with the TLR4/MD2 compared to other variants.J Genet Eng Biotechnol. 2024 Mar;22(1):100347. doi: 10.1016/j.jgeb.2023.100347. Epub 2024 Jan 22. J Genet Eng Biotechnol. 2024. PMID: 38494253 Free PMC article.
-
Acute Kidney Injury: Definition, Management, and Promising Therapeutic Target.Cureus. 2023 Dec 28;15(12):e51228. doi: 10.7759/cureus.51228. eCollection 2023 Dec. Cureus. 2023. PMID: 38283512 Free PMC article. Review.
-
Controlling viral inflammatory lesions by rebalancing immune response patterns.Front Immunol. 2023 Aug 21;14:1257192. doi: 10.3389/fimmu.2023.1257192. eCollection 2023. Front Immunol. 2023. PMID: 37671156 Free PMC article. Review.
References
-
- Kalil AC, et al. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock. 2011;36:327–331. - PubMed
-
- Mullarkey M, et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093–1102. - PubMed
-
- Thompson WW, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials